BMC Cancer · 2012 · 166 citations · 41 references
MedicineOncologyPharmacologyApoptosisGene ExpressionMolecular OncologyCancer Cell SignalingMolecular Tumor ProfilingNoncoding Rna In CancerSignal Transduction In CancerTumor Suppressor GenesAnticancer ActivityAnticancer Natural ProductsCancer Cell Proliferation InhibitionGrowth Inhibition AssaysMicrorna Function In CancerMicrorna In CancerMicrorna Regulation In CancerMicrorna-mediated Apoptosis Control
BACKGROUND: Curcumin inhibits growth of several cancer cell lines, and studies in this laboratory in bladder and pancreatic cancer cells show that curcumin downregulates specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 and pro-oncogenic Sp-regulated genes. In this study, we investigated the anticancer activity of curcumin and several synthetic cyclohexanone and piperidine analogs in colon cancer cells. METHODS: The effects of curcumin and synthetic analogs on colon cancer cell proliferation and apoptosis were determined using standardized assays. The changes in Sp proteins and Sp-regulated gene products were analysed by western blots, and real time PCR was used to determine microRNA-27a (miR-27a), miR-20a, miR-17-5p and ZBTB10 and ZBTB4 mRNA expression. RESULTS: The IC50 (half-maximal) values for growth inhibition (24 hr) of colon cancer cells by curcumin and synthetic cyclohexanone and piperidine analogs of curcumin varied from 10 μM for curcumin to 0.7 μM for the most active synthetic piperidine analog RL197, which was used along with curcumin as model agents in this study. Curcumin and RL197 inhibited RKO and SW480 colon cancer cell growth and induced apoptosis, and this was accompanied by downregulation of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 and Sp-regulated genes including the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-MET), survivin, bcl-2, cyclin D1 and NFκB (p65 and p50). Curcumin and RL197 also induced reactive oxygen species (ROS), and cotreatment with the antioxidant glutathione significantly attenuated curcumin- and RL197-induced growth inhibition and downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes. The mechanism of curcumin-/RL197-induced repression of Sp transcription factors was ROS-dependent and due to induction of the Sp repressors ZBTB10 and ZBTB4 and downregulation of microRNAs (miR)-27a, miR-20a and miR-17-5p that regulate these repressors. CONCLUSIONS: These results identify a new and highly potent curcumin derivative and demonstrate that in cells where curcumin and RL197 induce ROS, an important underlying mechanism of action involves perturbation of miR-ZBTB10/ZBTB4, resulting in the induction of these repressors which downregulate Sp transcription factors and Sp-regulated genes.
41
Anticancer potential of curcumin: preclinical and clinical studies.
Bharat B. Aggarwal, Anushree Kumar, Alok C. Bharti · PubMed · 2003 · 2.6K citations
Medicine, Oncology, Pharmacology +15
Ann‐Lii Cheng, Chih‐Hung Hsu, Jen‐Kou Lin et al. · PubMed · 2001 · 2.1K citations
Medicine, Oncology, Pharmacology +10
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo, Nicole L. Solimini, Stephen J. Elledge · Cell · 2009 · 1.8K citations · Full text
Medicine, Cancer Biology, Oncology +14
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Navneet K. Dhillon, Bharat B. Aggarwal, Robert A. Newman et al. · Clinical Cancer Research · 2008 · 1.3K citations
Medicine, Oncology, Pharmacology +15
Phase I Clinical Trial of Oral Curcumin
Ricky A. Sharma, Stephanie A. Euden, Sharon L. Platton et al. · Clinical Cancer Research · 2004 · 1.2K citations · Full text
Medicine, Oncology, Pharmacology +13